Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Madison, Wisconsin

Cancer biologic therapy trials in Madison, WI

34 cancer biologic therapy studies are recruiting participants at sites in Madison as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Madison at a glance

  • 34 studies are recruiting at a site in Madison.
  • By phase: Phase 1 (4), Phase 1/2 (2), Phase 2 (8), Phase 2/3 (2), Phase 3 (18).
  • By sponsor: industry (13), university, hospital or other (12), government (9).
  • By research area: Lymphoma (11), Breast Cancer (9), Lung Cancer (6), Melanoma (3), Pancreatic Cancer (3), Prostate Cancer (2).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Madison

Basic details from each study's public record (the 30 most recently updated of 34). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05564377 · updated
  2. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SSM Health Dean Medical Group ( Site 0087)
    Registry record
    NCT06393374 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Wisconsin-Madison ( Site 0024)
    Registry record
    NCT06966700 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT06058377 · updated
  5. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Circuit Clinical/SSM Health Dean Medical Group ( Site 0039)
    Registry record
    NCT07060807 · updated
  6. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040)
    Registry record
    NCT06312176 · updated
  7. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT06876714 · updated
  8. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05812807 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Lung cancer studies recruiting in Madison

  1. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital · William S Middleton VA Medical Center
    Registry record
    NCT04267848 · updated
  2. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)
    Registry record
    NCT06345729 · updated
  3. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT06616584 · updated
  4. Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital · William S Middleton VA Medical Center
    Registry record
    NCT05624996 · updated
  5. SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Verismo Therapeutics
    Study site
    University of Wisconsin Carbone Cancer Center
    Registry record
    NCT05568680 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Madison

  1. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    University of Wisconsin Carbone Cancer Center
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Melanoma studies recruiting in Madison

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    University of Wisconsin
    Registry record
    NCT06743126 · updated
  2. A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    University of Wisconsin Carbone Cancer Center
    Registry record
    NCT04511013 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Madison, WI on ClinicalTrials.gov.

Lymphoma studies recruiting in Madison

  1. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SSM Health Dean Medical Group ( Site 0140)
    Registry record
    NCT06717347 · updated
  2. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SSM Health Dean Medical Group ( Site 0106)
    Registry record
    NCT06890884 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05675410 · updated
  6. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT06649812 · updated
  7. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT03150693 · updated
  8. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05976763 · updated
  9. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT06124157 · updated
  10. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05633615 · updated
  11. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Madison, WI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Madison

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05372614 · updated
  2. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293)
    Registry record
    NCT06428409 · updated
  3. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Ask about studies near Madison

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Wisconsin

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call